Policy, funding, and public apathy hold back the search for more advanced COVID vaccines — but researchers persist and have ...
The CDC recommends that immunocompromised people and those age 65 and older should get a second dose of the 2024-2025 COVID ...
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...
Health Canada’s new COVID-19 vaccines targeting the KP.2 variant are available Monday. But with XEC on the rise, are they ...
the Food and Drug Administration authorized and approved updated COVID-19 vaccines that target JN.1-lineage omicron variants ...
Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...
The authors said the main outcomes of the study were reactogenicity, including fever, chills, muscle aches, and/or joint pain ...
Researchers investigate how public trust in the science of COVID-19 vaccines has changed in the United States.
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
The updated COVID-19 vaccines are available in the Eastern Ontario Health Unit (EOHU) region. Individuals who wish to receive ...
The CDC recommends that immunocompromised people age 65 and older should get a second dose of the 2024-2025 COVID vaccine.